ATE238784T1 - Granulat mit hohem gehalt an l-carnitine oder einem alkanoyl l-carnitine, insbesondere für die herstellung von direktverpressten tabletten - Google Patents

Granulat mit hohem gehalt an l-carnitine oder einem alkanoyl l-carnitine, insbesondere für die herstellung von direktverpressten tabletten

Info

Publication number
ATE238784T1
ATE238784T1 AT00917258T AT00917258T ATE238784T1 AT E238784 T1 ATE238784 T1 AT E238784T1 AT 00917258 T AT00917258 T AT 00917258T AT 00917258 T AT00917258 T AT 00917258T AT E238784 T1 ATE238784 T1 AT E238784T1
Authority
AT
Austria
Prior art keywords
carnitine
high content
granules
direct
alkanoyl
Prior art date
Application number
AT00917258T
Other languages
English (en)
Inventor
Ken Hassen
Original Assignee
Biosint S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosint S P A filed Critical Biosint S P A
Application granted granted Critical
Publication of ATE238784T1 publication Critical patent/ATE238784T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Confectionery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00917258T 1999-03-26 2000-03-22 Granulat mit hohem gehalt an l-carnitine oder einem alkanoyl l-carnitine, insbesondere für die herstellung von direktverpressten tabletten ATE238784T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000189A IT1305308B1 (it) 1999-03-26 1999-03-26 Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione
PCT/IT2000/000097 WO2000057873A2 (en) 1999-03-26 2000-03-22 Granulate with high content of l-carnitine or an alkanoyl l-carnitine

Publications (1)

Publication Number Publication Date
ATE238784T1 true ATE238784T1 (de) 2003-05-15

Family

ID=11406608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00917258T ATE238784T1 (de) 1999-03-26 2000-03-22 Granulat mit hohem gehalt an l-carnitine oder einem alkanoyl l-carnitine, insbesondere für die herstellung von direktverpressten tabletten

Country Status (20)

Country Link
US (1) US6485741B2 (de)
EP (1) EP1171111B1 (de)
JP (2) JP4637367B2 (de)
KR (1) KR100729848B1 (de)
CN (1) CN1158072C (de)
AT (1) ATE238784T1 (de)
AU (1) AU780413B2 (de)
CA (1) CA2363038C (de)
CZ (1) CZ301266B6 (de)
DE (1) DE60002454T2 (de)
DK (1) DK1171111T3 (de)
ES (1) ES2197867T3 (de)
HU (1) HU228588B1 (de)
IL (2) IL144957A0 (de)
IT (1) IT1305308B1 (de)
PL (1) PL207961B1 (de)
PT (1) PT1171111E (de)
SK (1) SK285565B6 (de)
TR (1) TR200102802T2 (de)
WO (1) WO2000057873A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383814C (en) * 1999-09-03 2010-08-17 Sigma-Tau Healthscience S.P.A. Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same
CN1686089B (zh) * 2005-05-08 2010-08-18 北京健健康康生物技术有限公司 一种可直接压片的木糖醇颗粒及其制备方法
ES2385046T3 (es) * 2005-07-05 2012-07-17 Lonza Ag Procedimiento de secado por pulverización para producir un polvo o granulado de carnitina seco
MX342962B (es) * 2009-09-18 2016-06-07 Teva Pharmaceuticals Holdings Mexico S A De C V Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma.
EP2335495A1 (de) 2009-12-11 2011-06-22 Lonza Ltd. Carnitin-Granulat und Verfahren zu dessen Herstellung
CN102349881B (zh) * 2011-10-26 2013-06-26 东北制药（沈阳）科技发展有限公司 一种左卡尼汀薄膜衣片及其制备方法
CN105695398A (zh) * 2016-04-25 2016-06-22 广西大学 含o-乙酰基-l-肉碱盐酸盐的水牛卵母细胞体外成熟液及培养方法
JP7366612B2 (ja) * 2019-07-09 2023-10-23 東和薬品株式会社 レボカルニチンを含有する錠剤
IL298209A (en) * 2020-05-15 2023-01-01 Alfasigma Spa Composition comprising methylfolate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2921852A1 (de) * 1979-05-29 1980-12-11 Fresenius Chem Pharm Ind Lipide senkendes mittel
IT1119853B (it) * 1979-09-21 1986-03-10 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente l-carnitina per il trattamento delle dislipidemie ed iperlipo proteinemie
JPS59222412A (ja) * 1983-06-01 1984-12-14 Earth Chem Corp Ltd 心臓疾患治療薬
DE3463261D1 (en) * 1983-12-28 1987-05-27 Sigma Tau Ind Farmaceuti Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1190370B (it) * 1985-06-19 1988-02-16 Zambon Spa Composizione farmaceutica solida per uso orale
JPH03120211A (ja) * 1989-10-04 1991-05-22 Earth Chem Corp Ltd 粒状カルニチン製剤
US5073376A (en) * 1989-12-22 1991-12-17 Lonza Ltd. Preparations containing l-carnitine
JPH0656659A (ja) * 1992-06-10 1994-03-01 Natl Sci Council 直接打錠できる薬学組成物及びその錠剤の製造法
EP0681839A3 (de) * 1994-05-12 1997-11-12 Hirohiko Kuratsune Acylcarnitin-enthaltende pharmazeutische Zusammensetzung
JPH0812569A (ja) * 1994-06-24 1996-01-16 Takeda Chem Ind Ltd 塩化カルニチン吸着固形物
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
JP3120211B2 (ja) 1996-05-14 2000-12-25 スガツネ工業株式会社 オーバーヘッドドア開閉用ダンパー
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
IT1291126B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti sali non igroscopici della l-carnitina e delle alcanoil l-carnitine
IT1291133B1 (it) * 1997-04-07 1998-12-29 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio tartrato
IT1290600B1 (it) * 1997-04-30 1998-12-10 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato

Also Published As

Publication number Publication date
SK11592001A3 (sk) 2001-12-03
WO2000057873A3 (en) 2001-04-19
SK285565B6 (sk) 2007-03-01
TR200102802T2 (tr) 2002-04-22
EP1171111A2 (de) 2002-01-16
HU228588B1 (en) 2013-04-29
JP4637367B2 (ja) 2011-02-23
HUP0200465A2 (en) 2002-06-29
WO2000057873A2 (en) 2000-10-05
ES2197867T3 (es) 2004-01-16
CN1345235A (zh) 2002-04-17
IL144957A (en) 2006-08-01
IT1305308B1 (it) 2001-05-04
US6485741B2 (en) 2002-11-26
KR20010114227A (ko) 2001-12-31
AU780413B2 (en) 2005-03-17
CN1158072C (zh) 2004-07-21
AU3834400A (en) 2000-10-16
PL207961B1 (pl) 2011-02-28
CA2363038C (en) 2008-10-14
US20020025984A1 (en) 2002-02-28
JP2001097353A (ja) 2001-04-10
DE60002454D1 (de) 2003-06-05
CA2363038A1 (en) 2000-10-05
JP2002540153A (ja) 2002-11-26
IL144957A0 (en) 2002-06-30
CZ20013078A3 (cs) 2002-02-13
EP1171111B1 (de) 2003-05-02
DK1171111T3 (da) 2003-08-25
ITRM990189A1 (it) 2000-09-26
PT1171111E (pt) 2003-09-30
DE60002454T2 (de) 2004-03-18
PL350908A1 (en) 2003-02-10
CZ301266B6 (cs) 2009-12-23
KR100729848B1 (ko) 2007-06-19

Similar Documents

Publication Publication Date Title
CA2091370A1 (en) Tablets, granulates and pellets with a high active substance content for highly concentrated, solid dosage forms
EP1435240A3 (de) Feste orale Dosierungsformen enthaltend eine Kombination von Glibenclamid und Metformin
NO841518L (no) Delbare tabletter med forsinket frigjoering av virkestoff, og fremgangsmaate for fremstilling derav
DK394685D0 (da) Pelletpraeparat og fremstilling deraf
FI863074A7 (fi) Farmaseuttisesti aktiivisten aineiden rakeinen, hidasluovutteinen muoto.
GEP20012580B (en) Substituted 4-Hydroxy-Phenylalcanoic Acid Derivatives With Agonist Activity to PPAR-Gamma, Methods for Their Production, Pharmaceutical Conposition and Methods for Treatment
NO933274L (no) Nye estere av bi- og tricykliske aminoalkoholer, samt fremstilling og anvendelse i legemidler
HUT61031A (en) Process for producing chemically modified, stable haemoglobin substituting for non-immunogehic red blood cell, and pharmaceutical compositions comprising same as active ingredient
AU2003286994A1 (en) Modified release pharmaceutical composition
ATE238784T1 (de) Granulat mit hohem gehalt an l-carnitine oder einem alkanoyl l-carnitine, insbesondere für die herstellung von direktverpressten tabletten
AU590370B2 (en) Improvements in or relating to pharmaceutical products
IL150528A0 (en) Ibuprofen containing active agent preparation
ATE423848T1 (de) Auslösender rezeptor der an der natürlichen cytotoxizität der menschlichen natürlichen killerzellen (natural killer cells) beteiligt ist und antikörper die diesen rezeptor identifizieren
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
AU4519399A (en) Anti-inflammatory pharmaceutical formulations
AU3970793A (en) Methods of manufacturing high dosage glutathione, the tablets and capsules produced thereby
AR033896A1 (es) Preparaciones granuladas de gaboxadol.
WO2002041897A3 (fr) Compositions pharmaceutiques a action antidiabetique constitues de l'association d'un biguanide et d'un sulfonamide
ZA853779B (en) The novel physiologically active substance foroxymithine,a process and microorganisms for its production and its use as medicament
TH13475A (th) สูตรผสมทางเภสัชกรรม
TH63676A (th) รูปปริมาณยาแบบปล่อยต่อเนื่องลำดับศูนย์และวิธีการผลิตสิ่งเดียวกัน
ATE10633T1 (de) Phenyl-chinolizidine, entsprechende pharmazeutische praeparate, die herstellung der wirkstoffe sowie entsprechende ausgangsverbindungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1171111

Country of ref document: EP